AIM: £46.30 (-0.7) | Nasdaq: $30.35 (-0.16)
Search
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
News Archive
Chi-Med
News
| Presentations
Previous Article
|
Next Article
Presentations
| 15 Oct 2013
ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents
1 Item
View Poster (PNG)